Jesse Pulido1, Adam J Sobczak, Jan Balzarini, Stanislaw F Wnuk. 1. Department of Chemistry and Biochemistry, ‡Department of Environmental and Occupational Health, Florida International University , Miami, Florida 33199, United States.
Abstract
The coupling of gemcitabine with functionalized carboxylic acids (C9-C13) or reactions of 4-N-tosylgemcitabine with the corresponding alkyl amines afforded 4-N-alkanoyl and 4-N-alkyl gemcitabine derivatives. The analogues with a terminal hydroxyl group on the alkyl chain were efficiently fluorinated under conditions that are compatible with protocols for (18)F labeling. The 4-N-alkanoylgemcitabines showed potent cytostatic activities in the low nanomolar range against a panel of tumor cell lines, whereas cytotoxicity of the 4-N-alkylgemcitabines were in the low micromolar range. The cytotoxicity for the 4-N-alkanoylgemcitabine analogues was reduced approximately by 2 orders of magnitude in the 2'-deoxycytidine kinase (dCK)-deficient CEM/dCK(-) cell line, whereas cytotoxicity of the 4-N-alkylgemcitabines was only 2-5 times lower. None of the compounds acted as efficient substrates for cytosolic dCK; therefore, the 4-N-alkanoyl analogues need to be converted first to gemcitabine to display a significant cytostatic potential, whereas 4-N-alkyl derivatives attain modest activity without measurable conversion to gemcitabine.
The coupling of gemcitabine with functionalized n class="Chemical">carboxylic acids (C9-C13) or reactions of 4-N-tosylgemcitabine with the corresponding alkyl amines afforded 4-N-alkanoyl and 4-N-alkyl gemcitabine derivatives. The analogues with a terminal hydroxyl group on the alkyl chain were efficiently fluorinated under conditions that are compatible with protocols for (18)F labeling. The 4-N-alkanoylgemcitabines showed potent cytostatic activities in the low nanomolar range against a panel of tumor cell lines, whereas cytotoxicity of the 4-N-alkylgemcitabines were in the low micromolar range. The cytotoxicity for the 4-N-alkanoylgemcitabine analogues was reduced approximately by 2 orders of magnitude in the 2'-deoxycytidine kinase (dCK)-deficient CEM/dCK(-) cell line, whereas cytotoxicity of the 4-N-alkylgemcitabines was only 2-5 times lower. None of the compounds acted as efficient substrates for cytosolic dCK; therefore, the 4-N-alkanoyl analogues need to be converted first to gemcitabine to display a significant cytostatic potential, whereas 4-N-alkyl derivatives attain modest activity without measurable conversion to gemcitabine.
Authors: Stijn L W Koolen; Petronella O Witteveen; Robert S Jansen; Marlies H G Langenberg; Roelien H Kronemeijer; Annemarie Nol; Ignacio Garcia-Ribas; Sophie Callies; Karim A Benhadji; Christopher A Slapak; Jos H Beijnen; Emile E Voest; Jan H M Schellens Journal: Clin Cancer Res Date: 2011-07-13 Impact factor: 12.531
Authors: F E Stuurman; E E Voest; A Awada; P O Witteveen; T Bergeland; P-A Hals; W Rasch; J H M Schellens; A Hendlisz Journal: Invest New Drugs Date: 2013-01-24 Impact factor: 3.850
Authors: J R Mackey; R S Mani; M Selner; D Mowles; J D Young; J A Belt; C R Crawford; C E Cass Journal: Cancer Res Date: 1998-10-01 Impact factor: 12.701
Authors: Johannes Schwarzenberg; Caius G Radu; Matthias Benz; Barbara Fueger; Andrew Q Tran; Michael E Phelps; Owen N Witte; Nagichettiar Satyamurthy; Johannes Czernin; Christiaan Schiepers Journal: Eur J Nucl Med Mol Imaging Date: 2010-12-03 Impact factor: 9.236
Authors: Jesse Pulido; Maria de Cabrera; Adam J Sobczak; Alejandro Amor-Coarasa; Anthony J McGoron; Stanislaw F Wnuk Journal: Bioorg Med Chem Date: 2018-10-12 Impact factor: 3.641
Authors: Cesar Gonzalez; Andersson Sanchez; Jeffrey Collins; Ksenia Lisova; Jason T Lee; R Michael van Dam; M Alejandro Barbieri; Cheppail Ramachandran; Stanislaw F Wnuk Journal: Eur J Med Chem Date: 2018-02-12 Impact factor: 6.514